Article
Pharmacogenomics panel test for prevention toxicity in patient who receive Fluoropirimidine/Oxaliplatin-based therapy.
European review for medical and pharmacological sciences - 1 Sept 2012
Di Francia R, Siesto R S, Valente D, Spart D, Berretta M
Abstract excerpt
AIM: Both Fluoropirimidine and Oxaliplatin (FluOx) are the most common anticancer drugs used to treat lung, colorectal, ovarian, breast, head/neck, and genitourinary cancers. However, the efficacy of FluOx-based therapy is often compromised because of the severe risk of toxicity. Stratification of patients for multidrug response is a promising strategy for cancer treatment and personalized therapy. METHODS: Here,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.